of stem cell research and deployment was initiated, although the term 'mesenchymal stem cells' was first coined by Caplan 3 
in 1991.
This item is fully connected with the problem of repair of vascular injury, mainly caused by therapeutic interventions aimed at removing endoluminal (atherosclerotic) obstacles by angioplasty that by definition destroy the endothelial layer. 4 It is well recognized that an intact endothelial layer is indispensible for proper reforming of the arterial wall, 5 to avoid overgrowth of arterial smooth muscle and excessive neointimal formation, 6 which may eventually lead to reocclusion of the artery just repaired. 7 And it is a very fortunate circumstance that the surviving endothelium still existing in the undamaged parts of the same vessel immediately starts expanding towards the centre of the lesion, thus ensuring a new endothelial layer 8 : this process, however, might be too slow to prevent the just mentioned overgrowth phenomena leading to reocclusion. But what if circulating cell elements, produced in the bone marrow or elsewhere, could contribute to the process? If this were the case, one could envision specific interventions aimed at enhancing the contribution of such elements, in order to speed up and optimize the reendothelialization process. 9 Indeed, there is wide evidence for the presence of a number of blood-borne foreign cells infiltrating the vessel wall at the site of the lesion, generally designed as circulating endothelial progenitor cells (EPCs), 10 but the exact location of these cells within the vascular wall has not been clearly established. The work by Hagensen et al. 11 ought to put an end to the search for methods for enhancing blood-borne EPCs to speed up reendothelialization, since it offers an amazingly plain demonstration of the exclusive involvement of adjacent existing endothelial cells in the process. Their experiments are based on a very elegant, although somewhat complicated, method of multiple arterial graft and cell tagging in a murine model. They used transgenic mice that preferentially express special fluorescent proteins in endothelial cells, as well as wild-type (WT) mice, and performed cross-transplantations of wire-injured common carotid artery segments. In addition, they further inserted a segment of WT-injured carotid within the cut stumps of the previously transplanted artery (non-injured). Mice were sacrificed after different periods and the arterial grafts were examined with multiple techniques that are suitable for determining endothelial denudation and progressive regeneration and for recognizing the origin of the newly formed endothelial cells. Thus, they were able to demonstrate complete reendothelialization within 10 days of the transplantation, with an influence of the direction of blood flow since the new cellular layer proceeded faster in the direction of flow than in the opposite direction. Interestingly, they did not find any isolated patches of endothelial cells in the centre of the graft, which suggested the lack of contribution of circulating EPCs to the process. But this circumstance was firmly reassessed when the arterial segments implanted within previously grafted, non-injured arterial segments were examined: not a single fluorescent element was found in the injured reendothelized segment inserted between two WT stumps in transgenic mice, whose circulating EPCs would be fluorescence-positive. Thus, the participation of circulating cell elements to the process of reendothelialization was definitely ruled out. The multiple visualization methods employed by the authors also allowed clarification of part of the contradictions of previous results claiming a role of circulating EPCs in the reendothelialization process, since they did find some fluorescence-tagged cells in the transplanted arterial segments in transgenic mice, but they clearly showed that such elements were located within, or in the vicinity of, the vascular wall and did not belong to the endothelium. This finding, while confirming their principal results, also leads to a possible
The opinions expressed in this article are not necessarily those of the Editors of Cardiovascular Research or of the European Society of Cardiology. criticism, and addresses new research, as acknowledged by the authors themselves. Circulating cell elements, probably originating in the bone marrow, or perhaps elsewhere, and stemming from totipotent stem cells, 12 may still play a very important role in endothelial regeneration by their action as paracrine machines, actively producing a bunch of molecules able to influence multiplication and growth of the underlying endothelial layer. 13 An issue that is not dealt with in the paper by Hagensen et al. 11 is the possible role of circulating EPCs, or analogous bone marrowderived cells, in tissue repair after a coronary occlusion and myocardial infarction. 14 This constitutes an entirely different scenario, however, in which the full angiogenesis process, not only endothelial proliferation, is stimulated and strongly enhanced by the inflammatory status that mobilizes several blood-borne elements, most of which come from the bone marrow. Therefore, I do not believe that the evidence provided by this paper contradicts the well-recognized role of stem cells of bone marrow origin in the revascularization of marginal areas following myocardial infarction. 15 In summary, the paper by Hagensen et al. is especially distinguished for its methodological completeness and clarity of results, although conclusions must be restricted to the case of post-injury arterial reendothelialization and cannot be extended to the wider area of de novo formation of blood vessels. Thus, totipotent stem cells do nothing in endothelial regeneration, but they can still do everything elsewhere.
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